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Omega-3 Fatty Acids Improve Recovery, whereas Omega-6
Fatty Acids Worsen Outcome, after Spinal Cord Injury in the
Adult Rat
Von R. King,* Wenlong L. Huang,* Simon C. Dyall, Olimpia E. Curran, John V. Priestley, and Adina T. Michael-Titus
Neuroscience Centre, Institute of Cell and Molecular Science, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, Queen Mary
University of London, London E1 2AT, United Kingdom
Spinal cord injury (SCI) is a cause ofmajor neurological disability, andno satisfactory treatment is currently available. Evidence suggests
that polyunsaturated fatty acids (PUFAs) could target someof thepathologicalmechanisms thatunderlie damageafter SCI.Weexamined
the effects of treatmentwith PUFAs after lateral spinal cord hemisection in the rat. The-3 PUFAs-linolenic acid and docosahexaenoic
acid (DHA) injected 30 min after injury induced significantly improved locomotor performance and neuroprotection, including de-
creased lesion size and apoptosis and increased neuronal and oligodendrocyte survival. Evidence showing a decrease in RNA/DNA
oxidation suggests that the neuroprotective effect of-3 PUFAs involved a significant antioxidant function. In contrast, animals treated
with arachidonic acid, an -6 PUFA, had a significantly worse outcome than controls. We confirmed the neuroprotective effect of -3
PUFAs by examining the effects ofDHA treatment after spinal cord compression injury. Results indicated thatDHAadministered 30min
after spinal cord compression not only greatly increased survival of neurons but also resulted in significantly better locomotor perfor-
mance for up to 6 weeks after injury.
This report shows a strikingdifference in efficacy between the effects of treatmentwith-3 and-6 PUFAson the outcomeof SCI,with
-3 PUFAs being neuroprotective and-6 PUFAs having a damaging effect. Given the proven clinical safety of-3 PUFAs, our observa-
tions show that thesePUFAshave significant therapeutic potential in SCI. In contrast, theuseof preparations enriched in-6PUFAsafter
injury could worsen outcome after SCI.
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Introduction
The devastating effects of spinal cord injury (SCI) are a result of
not only the initial injury but also a process of spreading second-
ary degeneration that affects both local neurons and glia, and en
passant axons. Several pathophysiological mechanisms underlie
this degeneration, including excitotoxicity (Hall and Braughler,
1986) and inflammation triggered bymacrophages andmicroglia
that release inflammatory cytokines (Profyris et al., 2004). Al-
though numerous treatments have targeted these pathogenetic
processes in preclinical studies (Leker and Shohami, 2002), most
have had limited success in clinical trials. One of the reasons for
this may be the complexity of the secondary degenerative re-
sponse. Many treatments affect only one aspect of this response,
and a successful treatment will probably have to target several of
these mechanisms.
Over the past 10 years, there has been increased interest in the
health benefits of polyunsaturated fatty acids (PUFAs), with evi-
dence emerging that -3 PUFAs have significant therapeutic po-
tential in neurology and psychiatry (Lauritzen et al., 2000; Emsley
et al., 2003). PUFAs are structural components of phospholipids,
which are themain constituents of cell membranes. PUFAs of the
-3 series include -linolenic acid (ALA), eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), the latter two being the
longer chain compounds, whereas ALA is the biosynthetic pre-
cursor. Recent evidence shows that -3 PUFAs can modulate
several of the processes that contribute to the secondary degen-
eration in the CNS. For example, -3 PUFAs have antioxidant
effects (Sarsilmaz et al., 2003) as well as anti-inflammatory effects
through inhibition of the production of proinflammatory cyto-
kines (Endres and von Schacky, 1996). PUFAs can also block
apoptosis (Martin et al., 2002), and several studies have docu-
mented their neuroprotective effects in vitro and in vivo (Blon-
deau et al., 2002; Wang et al., 2003). These observations suggest
that -3 PUFAs could have significant therapeutic potential in
the treatment of SCI.
The present study examined the effects of PUFA treatment in
a rat model of SCI. The -3 PUFAs ALA and DHA were injected
30 min after a spinal cord hemisection, and their effects were
studied on hindlimb locomotor function, lesion size, cell sur-
vival, and apoptosis. To begin to determine themechanismof any
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neuroprotective effect of PUFA treatment, we also examined the
degree of RNA/DNA oxidation, a process shown to be present in
both neurodegenerative diseases and after traumatic CNS injury
(Facheris et al., 2004). To establish whether any neuroprotective
effects were specific for -3 PUFAs, we also examined the effects
of the-6 PUFA arachidonic acid (AA) and the-9 monounsat-
urated fatty acid oleic acid (OA). AA and OA have complex pro-
files and have been shown to induce both neuroprotection and
neurodegeneration (Katsuki and Okuda, 1995; Toborek et al.,
1999; Rodriguez-Rodriguez et al., 2004), depending on the exper-
imental model. In addition, to further confirm the efficacy of-3
PUFAs after spinal cord injury, we examined the effects of DHA
treatment after spinal cord compression injury on neuronal sur-
vival as well as hindlimb locomotor recovery.
Materials andMethods
Animals and surgical procedures. Spinal cord hemisection and perfusion
were performed as described previously (King et al., 2004). All animal
procedures were approved by the United Kingdom Home Office. Adult
male Wistar rats (200–250 g) were anesthetized using 2–3% halothane,
the spinal cord between the T7 and T9 levels was exposed by laminec-
tomy, and a hemisection extending from themidline to the lateral edge of
the spinal cord was made with iris scissors. The lesion site was covered
with gelfoam, and the overlying muscle and skin were sutured. Thirty
minutes after hemisection, animals received a tail vein injection of vehi-
cle (n 8) or one of the following fatty acids at a dose of 250 nmol/kg, in
a volume of 5 ml/kg: the -3 PUFAs ALA (n 5) or DHA (n 10), the
-6 PUFA AA (n 5), or the -9 monounsaturated fatty acid OA (n
10). Fatty acids were dissolved at 1 M in ethanol and then diluted with
physiological saline, and solutions were adjusted to pH 7.4. All animals
survived for 1 week after surgery.
A second group of animals received a static compression injury of the
spinal cord as described previously (Nystrom et al., 1988; Huang et al.,
2006). Briefly, 22 animals were anesthetized using 2–3% halothane, and
the spinal cord at the T12 level was exposed by laminectomy. The T11
and T13 spinal processes were then clamped to prevent movement of the
spinal cord. A compression plate (area, 2  5 mm) that was suspended
from a platform via a metal rod was then placed on the dura of the
exposed spinal cord, and a 50 g weight was placed on the platform for 5
min. The lesion site was then closed (see above). Thirty minutes after
compression, animals received a tail vein injection of either vehicle or
DHA (see details above). The bladders of the animals were manually
voided twice a day for the first week and once daily thereafter until the
establishment of reflex voiding. Animals survived for either 7 d (vehicle,
n 5; DHA, n 5) or 6 weeks (vehicle, n 6; DHA, n 6).
At the appropriate postsurgical interval, animals were deeply anesthe-
tized with sodium pentobarbital (50 mg/kg, i.p.) and perfused through
the ascending aorta with 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4. The spinal cord was dissected out, postfixed in 4% para-
formaldehyde for 1–2 h, and cryoprotected in 15% sucrose, and then 10
m horizontal cryostat sections were cut through the hemisection site.
For animals that received static compression injury, transverse sections
through the entire rostrocaudal extent of the lesion site were taken.
Histochemistry. Sections were processed using standard immunofluo-
rescence procedures to the following antisera: mouse neuronal nuclear
antigen (NeuN) (1:200; Chemicon, Harrow, UK) to label neurons,
mouse adenomatous polyposis coli tumor suppressor protein (APC) (1:
200; Calbiochem, La Jolla, CA) to label oligodendrocytes, mouse glial
fibrillary acid protein (GFAP) (1:1000; Chemicon) to label astrocytes,
mouse ED1 (1:1000; Serotec, Oxford, UK) to label macrophages, and
mouse 8-hydroxyguanosine (oh8G) (1:1000; QED Biotech, San Diego,
CA) to label cells undergoing RNA/DNA oxidation. After 48 h of incu-
bation in primary antibody and washes in PBS, slides were incubated for
2 h in secondary antibody conjugated to tetramethylrhodamine isothio-
cyanate (1:400; Stratech Scientific, Cambridgeshire, UK) and then either
coverslipped in PBS glycerol or processed for terminal deoxynucleotidyl
transferase-mediated biotinylatedUTPnick end labeling (TUNEL) using
a terminal transferase-mediated dUTP nick end labeling kit (Promega,
Southampton, UK). This involved a 1 h incubation in biotinylated dUTP
and terminal deoxynucleotidyl transferase, followed by a 2 h incubation
in avidin extra fluorescein isothiocyanate (1:600; Sigma, Poole, UK).
To assess the effects on spinal tracts, sections were processed with the
myelin stain Luxol fast blue. Sectionswere incubated at 37°Covernight in
0.1%Luxol fast blue (Sigma) in 95%ethanol and 0.05%glacial acetic acid
and then differentiated in 1% lithium carbonate followed by 70% etha-
nol. Sections were then rinsed in tap water, dehydrated, and
coverslipped.
Behavioral assessment.Hindlimb locomotor function for animals that
received a spinal cord hemisection was assessed 1, 3, 5, and 7 d after
surgery in animals that received spinal cord hemisection. For the week
before surgery, animals were habituated and trained on all behavioral
tasks. The tasks used were as follows: (1) beam walk, (2) horizontal
ladder, and (3) open field. The beam walk test was similar to that de-
scribed by Metz et al. (2000). Animals were scored on their ability to
traverse 1.2-m-long wooden beams of three different widths (4.5, 3.5,
and 2.5 cm). The following scoring system was used: 0 for traversing less
than half the beam, 0.5 for traversing half the length of the beam, 1 for
traversing the whole beam, 1.5 for traversing the whole beam and show-
ing at least some stepping with the hindlimb ipsilateral to the lesion, and
2 for traversing the whole beam with accurate foot placement of the
hindlimb ipsilateral to the lesion. Animals that scored a zero on any beam
were not tested on narrower beams and were assigned a score of zero for
these beams. A maximum score of six was possible. In the horizontal
ladder test, animals were assessed on the number of footslips made when
crossing a 1-m-long horizontal ladder (11 cm wide with 5 cm between
each rung). A footslip was defined as a failure to at least partially grasp an
individual rung with the hindlimb ipsilateral to the lesion. In the open
field test, animals were placed in an open field and rated on a 21-point
scale for the use of the hindlimb ipsilateral to the side of the lesion, using
the Basso, Beattie, Bresnahan scale (BBB score) (Basso et al., 1996). An-
imals that received spinal cord compression and survived for 6 weeks
were assessed at 1 d, 1 week, 4 weeks, and 6 weeks after surgery on this
test.
Image and data analysis.The sections were viewed on a Leica (Wetzlar,
Germany) epifluorescence microscope using Y3 (tetramethylrhodamine
isothiocyanate) or L4 (fluorescein isothiocyanate) filter blocks. Images
were takenusing aHamamatsu (Herrsching,Germany)C4742–95 digital
camera and HiPic software (Hamamatsu). Figures were prepared using
Adobe Photoshop (Adobe Systems, San Jose, CA).
Quantitative analysis for the number of TUNEL-positive nuclei was
conducted by capturing an image of TUNEL labeling in the intact tissue
immediately rostral to the hemisection site. All TUNEL-positive nuclei
within the area were then counted in a 500 500 mmeasuring frame.
An identical procedure was conducted in the intact tissue immediately
caudal to the hemisection site. For each animal, a measure was taken in a
section through the dorsal horn, a section which included the central
canal and a section through the ventral horn. The cell counts in the six
sections were then used to determine the total number of TUNEL-
labeled cells per squaredmillimeter, measured around the lesion area for
each animal. Identical analyses were conducted for the number ofNeuN-
labeled and APC-labeled cells. A similar analysis was conducted for
oh8G-labeled cells, with the exception that only sections through the
dorsal horn and ventral horn were counted. In addition, for each animal,
an estimate of the lesion size was made by tracing the area within the
borders of the lesion as defined by GFAP labeling (see Fig. 1) through a
section that included the central canal. A similar quantitative analysis of
NeuN-labeled cells was conducted in animals that received spinal cord
compression. Briefly, all NeuN-labeled cells within a 100  100 m
measuring frame placed within the dorsal and ventral horns on both the
left and right sides were counted. Identical measures were taken from six
equally spaced sections throughout the center of the lesion for each ani-
mal, and the number of NeuN-labeled cells per squared millimeter was
determined.
For all quantitative analysis of anatomical data, measures were made
with the experimenter blind to the animals’ treatment group. For each of
the above measures, an ANOVA was conducted comparing the treat-
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ment groups, followed by post hoc analysis
when appropriate. For behavioral data, two-
way repeated-measures ANOVA were con-
ducted comparing the treatment groups over
the number of test sessions for a particular be-
havioral task, followed by post hoc analysis
when appropriate.
Results
Spinal cord hemisection
Lesion size
Seven days after hemisection injury, the
lesion site appeared as an area devoid of
GFAP staining, which extended from the
midline to the lateral edge of the spinal
cord (Fig. 1A–C). The lesion extent was
visibly smaller in DHA- and ALA-treated
animals compared with OA- and vehicle-treated animals (Fig.
1A,B). In addition, AA-treated animals had larger lesions than
the other four groups, and in the case of two animals showed
“islands” of damage that were discontinuous with the original
lesion site (Fig. 1C). Quantitative analysis confirmed that DHA-
and ALA-treated animals had significantly smaller lesions than
either OA- or vehicle-treated animals (all comparisons, p 
0.05), and that AA-treated animals (Fig. 1C) had significantly
larger lesions than all other groups (Table 1).
Apoptosis
TUNEL-labeled nuclei (Fig. 2A) were clearly visible, and coun-
terstaining with 4,6-diamidino-2-phenylindole (Fig. 2B) con-
firmed chromatin condensation and fragmentation in the nuclei
of TUNEL-labeled cells. TUNEL labeling was present in all
groups at 7 d after hemisection injury, with the vast majority of
apoptotic nuclei present within 500 m of the lesion site. Quan-
titative analysis showed that DHA- and ALA-treated animals had
significantly fewer (30–40%) TUNEL-labeled cells than OA-,
AA-, and vehicle-treated animals (all comparisons, p  0.05)
(Table 1). In contrast, AA treatment resulted in significantly
more TUNEL-labeled nuclei than control animals ( p  0.05).
Double labeling using immunofluorescence to label neurons
(Fig. 2C, NeuN) or oligodendrocytes (Fig. 2D, APC) showed that
approximately equal percentages of these cell types had apoptotic
nuclei, although most TUNEL-labeled cells were not APC or
NeuN immunoreactive. In contrast, no astrocytes (GFAP-labeled
cells) were seen with TUNEL-positive nuclei. It is not clear in
what type of cells the remaining TUNEL-positive nuclei were
present. However, it is possible that a loss of antigencity in dying
oligodendrocytes or neurons prevented double labeling from oc-
curring in some cells that were actually undergoing apoptosis.
oh8G labeling
oh8G immunoreactivity appeared as punctate cytoplasmic label-
ing, with little or no labeling within the nucleus itself (Fig. 3). Few
labeled cells were seen in the white matter. This, combined with
themorphological appearance of labeled cells, suggests that most
oh8G-positive cells were neurons. DHA- and ALA-treated ani-
mals had visibly fewer oh8G-positive cells (Fig. 3B) than either
the control (Fig. 3A) or OA-treated animals. In contrast, AA
treatment resulted in a clear increase in oh8G labeling (Fig. 3C,
Table 1) compared with the other groups. This increase was seen
not only adjacent to the lesion site but also at several millimeters
from the lesion, in an areawhere oh8G labelingwas not present in
the other groups. ANOVA confirmed significant differences be-
tween the PUFA-treated groups in the number of oh8G-labeled
cells adjacent to the lesion site in both the dorsal and ventral
horns (both comparisons, p 0.001). Subsequent post hoc anal-
ysis showed that in the ventral horn, there were fewer oh8G-
labeled cells in theDHA- andALA-treated groups comparedwith
the other groups, whereas AA-treated animals had significantly
more labeled cells than all other groups (all comparisons, p 
0.05). Similar results were seen in the dorsal horn, with the ex-
ception that ALA-treated animals were not significantly different
from OA-treated or control animals in the number of oh8G-
labeled cells.
Neurons
Seven days after hemisection injury, the number ofNeuN-labeled
nuclei (Fig. 4A–C) present in the intact tissue adjacent to the
lesion site was greater in ALA- and DHA-treated animals com-
pared with vehicle-, AA-, and OA-treated animals. This differ-
ence was most pronounced in tissue immediately adjacent to the
lesion site, where numerous NeuN-labeled cells were present in
ALA- and DHA-treated animals, but very few labeled cells were
present in the remaining groups.Quantitative analysis confirmed
these differences, with significantly more NeuN-labeled neurons
after DHA and ALA treatment compared with the remaining
groups (all comparisons, p  0.05) (Table 1). In addition, AA-
treated animals had significantly fewer NeuN-labeled cells than
vehicle controls ( p  0.05) and also appeared to have smaller
neurons than those in the other groups.
Oligodendrocytes and myelin
Analysis of APC labeling showed a similar effect to that for NeuN
labeling, with DHA- and ALA-treated animals clearly having
more APC-labeled oligodendrocytes than vehicle-, OA-, andAA-
treated animals (Fig. 4D–F). Quantitative analysis confirmed
that DHA- and ALA-treated animals had significantly more
APC-labeled oligodendrocytes than these groups (all compari-
sons, p  0.05) (Table 1) and also showed that AA-treated ani-
mals had significantly fewer APC-labeled cells than all other
groups (Table 1) (all comparisons, p  0.05). The protective
effect of ALA and DHA on oligodendrocytes was also reflected in
the results obtainedwith themyelin stain, Luxol fast blue (Fig. 5).
Although myelin in the white matter ipsilateral to the lesion
showeddegeneration in all groups (Fig. 5A,B) comparedwith the
corresponding white matter contralateral to the lesion (Fig. 5C),
myelin ipsilateral to the lesion in DHA-treated (Fig. 5D) and
ALA-treated animals clearly showed less vacuolization and dis-
ruption compared with the other three groups (Fig. 5E). This
decreased degenerationwas seen severalmillimeters from the site
of injury.
Figure1. GFAP labeling at the spinal cord hemisection site after a single intravenous injection of either saline or PUFAs after 7 d
of survival. Vehicle (A) and OA-treated (not pictured) animals had similarly sized lesions that extended laterally from the midline
of the spinal cord. Lesions in animals treated with DHA (B) or ALA (not pictured) were similar, with both groups having smaller
lesions than either vehicle- or OA-treated animals. In contrast, AA-treated animals (C) had greatly expanded lesions, with some
animals showing islands of damage discontinuous with the original lesion site (arrow). Scale bar, 200m.
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Macrophages
Examination of ED1 labeling indicated that there was no differ-
ence in the density of ED1-positive macrophages within the le-
sion site for any of the treatment groups (Table 1). However,
AA-treated animals had a higher density of ED1 labeling in the
intact tissue adjacent to the lesion, compared with the other four
groups (all comparisons, p  0.05) (Table 1), and this increase
was apparent as far as 2–3 mm from the lesion site.
Locomotor behavior
All animals obtained maximum scores for each task (21 on the
BBB, 6 on the beam walk, and 0 errors on the horizontal ladder)
during the 3–4 d of training and habituation before receiving
injury. Postsurgically, DHA- and ALA-treated animals per-
formed significantly better than the remaining groups on all three
behavioral tests during the latter days of testing (days 5–7).
In the open field, at least some plantar stepping was present in
the majority of DHA- and ALA-treated animals by the seventh
day after surgery, whereas plantar step-
ping was present in no more than two
animals in each of the vehicle-, OA-, or
AA-treated animals. Statistical analysis
confirmed that ALA- and DHA-treated
animals had significantly greater scores on
ratings of hindlimb locomotor use in the
open field BBB score (Basso et al., 1996)
than the remaining three groups ( p 
0.05) during the third, fifth, and seventh
day after surgery (all comparisons, p 
0.05), whereas the vehicle-, OA-, and AA-
treated groups did not differ at any time
point (Fig. 6A).
ALA- and DHA-treated animals also
performed better on the beam walk task,
with all but two animals from each of these groups able to walk
completely across the 3.5 cm beam and a majority of animals in
each of these groups able to walk completely across the 2.5-cm-
wide (narrowest) beam by 7 d after surgery. In contrast, fewer
than half of the animals in each of the vehicle-, OA-, and AA-
treated groups were able to cross completely the 3.5-cm-wide
beam, with at least one animal in each group unable to walk
completely across the widest beam (4.5 cm) by the seventh day
after surgery. Statistical analysis showed that animals in the ALA-
and DHA-treated groups had significantly better scores on the
beam walk task during the fifth and seventh days after surgery
than the vehicle-, OA-, and AA-treated groups (all comparisons,
p 0.05) (Fig. 6B). The three latter groupswere similar at all time
points.
Results from the horizontal ladder showed that although both
ALA and DHA significantly decreased the number of footslips of
the hindpaw ipsilateral to the lesion, DHA had a slightly greater
Table 1. Effects of PUFA treatment on lesion size and cell survival 7 d after hemisection injury
Vehicle
(saline)
ALA
(omega-3 PUFA)
DHA
(omega-3 PUFA)
OA
(omega-9 MUFA)
AA
(omega-6 PUFA)
Lesion size (mm²) 0.52 0.06 0.30 0.03a 0.32 0.05a 0.64 0.05 0.86 0.05b
TUNEL plus nuclei (per mm²) 8.67 0.91 6.51 0.87a 5.42 0.73a 9.57 1.03 11.21 1.21c
NeuN plus cells (per mm²) 60.42 4.26 81.47 6.68a 88.87 3.54a 58.15 3.23 49.33 2.37c
APC plus cells (per mm²) 35.78 1.47 41.76 1.29a 39.74 2.40a 33.28 2.44 29.70 1.49c
ED1, within lesion (%) 17.72 3.79 13.72 4.31 19.41 4.01 16.89 2.98 28.62 4.91
ED1, outside lesion (%) 33.67 5.57 28.91 4.91 36.72 6.02 29.71 4.48 41.22 7.09b
oh8G plus cells, dorsal (per mm²) 14.70 0.82 10.90 1.20 8.30 0.82a 14.40 2.30 22.50 2.50b
oh8G plus cells, ventral (per mm²) 10.10 0.76 5.80 0.62a 5.30 0.64a 10.60 1.60 15.20 2.36b
aSignificantly different from vehicle-, AA-, and OA-treated animals (p 0.05).
bSignificantly different from all other groups (p 0.05).
cSignificantly different from vehicle-, DHA-, and ALA-treated animals (p 0.05).
Figure2. TUNEL labeling of apoptotic nuclei adjacent to the spinal cord hemisection site after a single intravenous injection of either saline or PUFAs after 7 d of survival. TUNEL-labeled nuclei (A)
were clearly identifiable in all treatment groups and were confirmed by counterstaining with the nuclear stain 4,6-diamidino-2-phenylindole (B) (corresponding arrows in A and B show
double-labeled nuclei). Double labeling (C) for TUNEL (green) and NeuN (red) showed occasional apoptotic nuclei within neurons (arrows). Similarly, double labeling (D) for APC (red) and TUNEL
(green) showed occasional double-labeled oligodendrocytes (arrow). Numerous TUNEL single-labeled cells were also present (arrowhead). Scale bars: A–D, 50m.
Figure 3. oh 8G labeling of RNA/DNA oxidation in cells adjacent to the spinal cord hemisection site after a single intravenous
injection of either saline or PUFAs after 7 d of survival. The number of oh 8G-labeled neurons in the area immediately adjacent to
the lesion site in vehicle-treated (A) and OA-treated (not pictured) animals was similar. Both of these groups had noticeablymore
oh 8G-labeled cells than either DHA-treated (B) and ALA-treated (not pictured) animals, which had few oh 8G-labeled cells. In
contrast, AA-treated animals (C) had substantially more oh 8G-labeled cells than all other groups. Scale bar, 50m.
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effect than ALA, resulting in fewer foot-
slips than all other groups (including the
ALA group) at 5 d after surgery ( p 
0.05), whereas both the ALA and DHA
groups had fewer ipsilateral footslips than
the remaining three groups at 7 d after sur-
gery ( p 0.05) (Fig. 6C). Analysis of foot
slips of the hindlimb contralateral to the
lesion showed a different pattern (Fig.
6D). Most notably, DHA but not ALA re-
sulted in significantly fewer hindlimb slips
compared with vehicle controls (all com-
parisons, p  0.05). In addition, this im-
provement was seen earlier (at the first
and third days after surgery) than in the
other measures of locomotor function.
Last, AA resulted in significantly worse
performance than not only the DHA- and
ALA-treated groups but also the vehicle
control group at 1, 3, and 5 d after surgery
( p 0.05).
Spinal cord compression injury
Neurons
Examination of NeuN labeling after spinal
cord compression confirmed the neuro-
protective effects of DHA treatment seen
after spinal cord hemisection. Specifically, DHA-treated animals
clearly had more NeuN-labeled cells than saline-treated animals
in all areas of the gray matter at both 1 week (Fig. 7A,B) and 6
weeks after injury (Fig. 7C,D). Quantitative analysis (Fig. 7E)
confirmed that control (saline-treated) compression injury ani-
mals had significantly fewer NeuN-labeled cells at 1 week (56%
decrease) and 6 weeks (66% decrease) after surgery compared
with DHA-treated animals ( p values0.05).
Locomotor behavior
On the first day after surgery, the DHA- and saline-treated ani-
mals did not have significantly different BBB scores (Fig. 8), with
all animals in both groups showing little or no movement of
either hindlimb. By 1week after surgery, although bothDHA and
saline-treated animals had improved hindlimb locomotor func-
tion, DHA-treated animals had clearly shown more improve-
ment with significantly higher open field ratings (3 points on
the BBB scale) than saline-treated animals ( p 0.05). By 6weeks
after surgery, although hindlimb locomotor performance of both
DHA- and saline-treated animals had improved, animals treated
with DHA maintained significantly better hindlimb locomotor
performance compared with saline-treated controls ( p 0.05).
Discussion
This study demonstrates for the first time that -3 PUFAs are
neuroprotective in traumatic SCI and shows that, in contrast,
exposure to -6 PUFAs in the aftermath of injury could signifi-
cantly worsen outcome. ALA or DHA treatment 30 min after
hemisection of the spinal cord resulted in decreased lesion size,
reduced apoptotic cell death, increased neuronal and oligoden-
drocyte survival, and improved locomotor function. The efficacy
of -3 PUFA treatment was confirmed in a compression model
of spinal cord injury, with DHA treatment resulting in increased
neuronal survival, as well as improved locomotor performance as
long as 6 weeks after surgery. In striking contrast, AA exacerbated
damage and led to worse locomotor performance. Each of these
aspects will be briefly discussed, together with the possible mech-
anisms underlying the neuroprotection and the implications for
clinical use of PUFAs in SCI.
Lesion size after hemisection SCI was reduced by 40–45%
by DHA and ALA injection. The reduction in lesion size is likely
to be partly attributable to decreased cell death, a conclusion
consistent with our finding of increased numbers of NeuN-
immunoreactive neurons and APC-immunoreactive oligoden-
drocytes in the perilesional area. Although loss of immunoreac-
tivity does not necessarily indicate cell death (Unal-Cevik et al.,
2004), TUNEL labeling confirmed that both neurons and oligo-
dendrocytes underwent apoptosis and that the -3 PUFAs re-
duced apoptotic death by 25%(ALA) and 38%(DHA).Cell death
after SCI involves both necrosis and apoptosis, with necrosis
prominent at the lesion epicenter and extensive oligodendrocyte
apoptosis in degenerating white matter tracts (Yong et al., 1998;
Beattie et al., 2000). Although we did not assess necrosis, the
decreased lesion size indicates that necrotic cell death is also likely
to have been reduced. These protective effects are comparable
with the observations of Lang-Lazdunski et al. (2003), who
showed that apoptosis induced in the spinal cord after prolonged
ischemia can be decreased by an injection of ALA at the onset of
reperfusion.
Several possible mechanisms may underlie the reduced neu-
ronal death that we observed. The decreased oh8G staining after
ALA and DHA treatment suggests that a reduction in oxidative
stress, an immediate consequence of SCI (Hall and Braughler,
1986; Xu et al., 2005) that leads to dysfunction of mitochondria
and subsequent neuronal death (Sullivan et al., 2005), is involved
in the neuroprotective effects of ALA andDHA. This possibility is
supported by studies showing that DHA increases the activity of
antioxidant enzymes such as glutathione peroxidase and gluta-
thione reductase in hippocampal cells in culture (Wang et al.,
2003), and that-3 PUFAs enhance in vivo the activity of antiox-
idant systems in the CNS (Sarsilmaz et al., 2003; Songur et al.,
2004). In addition,-3 PUFAs are not only neuroprotective in rat
Figure 4. NeuN labeling of neurons and APC labeling of oligodendrocytes adjacent to the spinal cord hemisection site after a
single intravenous injection of either saline or PUFAs after 7 d of survival. The number of NeuN-labeled neurons in the area
immediately adjacent to the lesion site in vehicle treated (A) and OA-treated (not pictured) animals was similar. Both of these
groups had noticeably fewer NeuN-labeled cells than DHA-treated (B) and ALA-treated (not pictured) animals, which had similar
numbers of neurons. In contrast, AA-treated animals (C) had substantially fewer NeuN-labeled neurons than all other groups.
Similar results were seen with APC-labeled oligodendrocytes, with vehicle-treated (D) and OA-treated (not pictured) animals
having fewer cells than DHA-treated (E) and ALA-treated (not pictured) animals. AA-treated animals (F ) had fewer oligodendro-
cytes than the other groups. Scale bar: (in A) A–F, 250m.
4676 • J. Neurosci., April 26, 2006 • 26(17):4672–4680 King et al. • Omega-3 PUFAs Improve Recovery after SCI
models of neurotoxicity (Zararsiz et al., 2005) and forebrain isch-
emia (Blondeau et al., 2002; Cao et al., 2004) but also attenuate
decreases in the CNS levels of antioxidant enzymes (e.g., catalase,
superoxide dismutase, and glutathione peroxidase) in these
models. To more clearly address the antioxidant role of DHA
treatment, studies in our laboratory examining the effects of
DHA treatment after spinal cord injury on both lipid peroxida-
tion and protein oxidation are currently underway. It should also
be noted that ALA and DHA may mediate their neuroprotective
effects by reducing glutamate-induced excitotoxicity. In vitro and
in vivo studies have shown that -3 PUFAs reverse glutamate-
induced excitotoxicity (Hogyes et al., 2003; Wang et al., 2003),
which is known to be one of the triggers of apoptosis after SCI
(Xu et al., 2004). Similar mechanisms may also underlie the pro-
tective effects of -3 PUFAs on oligodendrocytes, because exci-
totoxicity also plays a role in their death (Park et al., 2004).
The striking difference in the neuroprotective efficacy of the
-3 and -6 PUFAs seen in the current study also implicate
effects on the inflammatory cascade that occurs after SCI. AA is
metabolized by cyclooxygenase (COX) enzymes to two-series
prostaglandins and thromboxanes, such as prostaglandin E2 and
by 5-lipoxygenase to produce leukotrienes
such as leukotriene B4. These metabolites
enhance vascular permeability, increase
local blood flow, increase infiltration of
leukocytes, and enhance production of
proinflammatory cytokines such as tumor
necrosis factor , interleukin 1 (IL-1) and
IL-6. In contrast, -3 PUFAs can decrease
COX activity and the formation of proin-
flammatory eicosanoids and cytokines
(Calder, 2003; Lonergan et al., 2004). SCI
results in an increase in tissue AA concen-
tration of up to 20 times (Murphy et al.,
1994), and recruitment of neutrophils,
macrophages, and microglial cells at the
injury site (Dusart and Schwab, 1994).
Antagonism of this deleterious cascade
may therefore have contributed to the
neuroprotective effects of DHA. In con-
trast, acute AA administration after injury
could be expected to augment inflamma-
tion and increase cell death, as observed in
our study.
It should be noted that the neuropro-
tective effects of the two tested-3 PUFAs
(ALA andDHA)may bemediated, at least
in part, by different mechanisms. The
finding that only 0.2%ofALA is converted
to DHA in the rat suggests that the neuro-
protective effect of ALA is not simply a
result of its conversion into DHA (Demar
et al., 2005). A direct neuroprotective
mechanism of action could involve two-
pore potassium channels, such as TWIK-
related potassium channel (TREK) and
TWIK-related arachidonic acid-
stimulated potassium channel (TRAAK),
at which ALA and DHA have significant
affinity (Lauritzen et al., 2000; Emsley et
al., 2003). In addition, it has been shown
thatDHA can lead to the formation ofme-
diators such as 10,17S-docosatriene (neu-
roprotectin D1), an endogenous compound with anti-oxidant
(Bazan, 2005) as well as anti-inflammatory (Mukherjee et al.,
2004) effects. ALA is converted in vivo to EPA, which is a precur-
sor of the anti-inflammatory series-3 prostaglandins and also in-
hibits conversion of AA to proinflammatory prostaglandins and
leukotrienes (Needleman et al., 1979). Recent pilot data in our
laboratory show that EPA is neuroprotective in SCI and support
the possibility that some of the effects of DHA are caused by
conversion to EPA. Finally, the neuroprotective effect of DHA
may also involve a complex pattern of activation of gene tran-
scription, for example through retinoid receptor signaling
(Jump, 2002). We have not yet performed detailed pharmacoki-
netic studies, and we have not analyzed the incorporation of the
PUFA in the nervous tissue after the intravenous bolus injection
in the rat, but by analogy with what has been reported in studies
with radiolabeled AA (Jones et al., 1996), it is likely that a fraction
of the injected DHA entered the CNS (1% reported for AA in
animals with an intact blood–brain barrier) and was incorpo-
rated rapidly in phospholipids. We injected a bolus of DHA so-
lution at 62.5M, and the freeDHA in rat plasma is reported to be
10.6 M, whereas the free DHA in brain is 1.3 M (Calderon
Figure 5. Luxol fast blue staining of the lateral whiter matter after spinal cord hemisection in animals that received a single
intravenous injection of either saline or PUFAs after 7 d of survival. The appearance of myelin staining at the lesion site in
vehicle-treated (A), DHA-treated (B), and ALA-, OA-, and AA-treated (not pictured) animals was similar, with all groups showing
a lack of staining in thewhitematter ipsilateral to the lesion. Adjacent to the lesion site, themyelin in thewhitematter ipsilateral
to the hemisection was disrupted relative to the uninjured side (C, enlargement of area within the top box in A) in all groups.
However, myelin in ALA-treated (not pictured) and DHA-treated (D, enlargement of area within the box inB) animals was clearly
less disrupted compared with OA-, AA-, and vehicle-treated animals (E, enlargement of area within the bottom box in A), which
had large cavities in the whitematter several millimeters from the lesion site. Scale bars: (in A) A, B, 250m; (in C) C–E, 25m.
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andKim, 2004). Therefore, the concentrations of DHA remained
in a physiological range andwere also compatiblewith the affinity
of this fatty acid for targets such as TRAAK/TREK or retinoid
receptors, which may be activated by the free DHA, thus being
mechanistically involved in the neuroprotection seen.
The decreased lesion size and cell death obtained with ALA
and DHA were mirrored by improved locomotor performance.
This was seen in both a more rapid recovery and improved level
of locomotor performance. This very close correspondence be-
tween the histological and behavioral parameters was seen as late
as 6 weeks after spinal cord compression and means that it is
highly likely that the functional improvements seen with -3
PUFAs are a direct consequence of the decreased lesion size and
decreased cell death. The large increase in the number of NeuN-
labeled neurons seen after -3 treatment in both injury para-
digms suggests that this reduced secondary degeneration reflects
increased survival of neurons. However, our data on oligoden-
drocyte survival and myelin integrity (Luxol fast blue) would
indicate that it is also likely to reflect reduced damage to ascend-
ing and descending tracts. It is also important to note that -3
fatty acids have been shown to have neurite growth-promoting
effects in hippocampal neurons (Calderon and Kim, 2004). We
recently confirmed such trophic effects in our laboratory, in stud-
ies on primary sensory neurons in culture (L. G. Robson, D.
Sidloff, S. C. Dyall, and A. T. Michael-Titus, manuscript in prep-
aration). Omega-3 compoundsmay therefore have not only neu-
roprotective but also neuroregenerative effects after SCI.
Together, our data suggest that -3 PUFAs have significant
therapeutic potential in SCI and are consistent with results with
these PUFAs in other models of CNS injury (Blondeau et al.,
2002; Cao et al., 2004; Zararsiz et al., 2005). However, some issues
deserve additional investigation. For example, before recommen-
dations for clinical use, the choice of compound anddosemust be
further explored and optimized. The dose of DHA we injected
intravenous (250 nmol/kg; i.e., 82g/kg) is very small compared
with the doses of EPA and DHA taken orally by patients in fish
oil-containing preparations (e.g., 3–6 g/d) or compared with the
intake of DHA as part of lipid preparations administered paren-
terally in the clinic (e.g., 2.15 g of DHA/100 ml in fish oil-
enriched suspensions) (Mayser et al., 2002). Therefore, this neu-
roprotective dose range could be easily translated to the clinic for
use as an intravenous bolus after trauma. Heurteaux et al. (2005)
recently showed that ALA treatment can be delayed up to 3 h and
still induce significant neuroprotection after cerebral ischemia in
themouse. It is therefore important to determinewhether similar
(or longer) delays in -3 PUFA treatment after SCI still confer
neuroprotection. Similarly, the route of administration of these
compounds after injury is of interest for their clinical application.
Figure 6. Locomotor performance after spinal cord hemisection in animals that received a
single intravenous injection of either saline or PUFAs. Both ALA- and DHA-treated animals
performed significantly better on the BBB open field (A) and the beamwalk (B) tasks than the
remaining groups, which did not differ. DHA- and ALA-treated animals also had significantly
fewer foot slipswith the hindlimb ipsilateral to the lesion on the horizontal ladder (C) compared
with the other groups, although this difference was only seen for the ALA group at 7 d after
surgery. In contrast, DHA- but not ALA-treated animals showed significantly fewer slips with
the hindlimb contralateral to the lesion, compared with vehicle- and OA-treated animals,
whereas AA-treated animals were worse on this parameter than all of the other groups (D).
*DHA- and ALA-treated animals significantly different from remaining groups ( p  0.05);
#DHA-treated animals significantly different from the remaining groups ( p  0.05);,
vehicle-, DHA-, and ALA-treated animals significantly different from AA-treated animals
( p 0.05).
Figure 7. NeuN labeling of neurons after spinal cord compression and a single intravenous
injection of either DHA or saline. At 1 week after surgery, the number of NeuN-labeled cells in
saline-treated animals (A) was substantially less than naive control animals (E). DHA-treated
animals (B, D) also had more NeuN-labeled neurons compared with saline-treated (A, C) ani-
mals at both 1 and 6 weeks after surgery. Quantitative analysis (F ) confirmed that there were
significantly more NeuN-labeled neurons in DHA-treated animals at both 1 week and 6 weeks
after surgery compared with saline-treated controls. Scale bar: (in E) A–E, 50 m. *DHA-
treated animals significantly different from saline-treated controls ( p 0.05). Error bars rep-
resent SEM.
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Initial evidence indicates that -3 PUFAs are also neuroprotec-
tive after spinal cord injury when given via the diet (Huang et al.,
2005). This is particularly relevant for the clinical situation, in
light of the current use of lipid emulsions for nutritional support
in a variety of patient populations, including surgical and criti-
cally ill patients (Calder, 2003).
Omega-3 PUFA preparations have been shown previously to
be safe andwell tolerated in patients in several diseases (Schlanger
et al., 2002), which reinforces their potential for rapid translation
into clinical use in SCI. Their significant potential in neurology is
demonstrated by the remarkable efficacy of DHA in Zellwegger’s
syndrome (Martinez et al., 2000). In addition, as noted above,
lipid emulsions are already given as nutritional support to a va-
riety of vulnerable patient populations (Calder, 2003). However,
most preparations used at present contain a significant amount
of soybean oil and therefore have a considerable -6 component
that, according to our results with AA, could worsen outcome
after SCI. In contrast, acute -3 PUFA administration after
trauma as a neuroprotective treatment would confer clear advan-
tages and deserves consideration as a promising innovative ap-
proach in SCI management, with easy transfer to the clinic.
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